PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes. (Q51203144)

1 April 2018

title

PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes. (English)

1 reference

1 April 2018

0 references

0 references

Guoliang Ding

1

1 reference

1 April 2018

Lihong Cheng

2

1 reference

1 April 2018

Qianhong Qin

3

1 reference

1 April 2018

Sonya Frontin

4

1 reference

1 April 2018

Qinglin Yang

5

1 reference

1 April 2018

publication date

15 May 2006

1 reference

1 April 2018

Journal of Molecular and Cellular Cardiology

published in

1 reference

1 April 2018

volume

40

1 reference

1 April 2018

page(s)

821-828

1 reference

1 April 2018

issue

6

1 reference

1 April 2018

Anti-tumor necrosis factor-alpha improves myocardial recovery after ischemia and reperfusion

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

Fenofibrate, a peroxisome proliferator-activated receptor alpha activator, suppresses experimental autoimmune myocarditis by stimulating the interleukin-10 pathway in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

Transcriptional repression of atherogenic inflammation: modulation by PPARdelta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

Peroxisome proliferator-activated receptor delta activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure. VEST Investigators for TNF Genotype Analysis. Vesnarinone Survival Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

Increased circulating cytokines in patients with myocarditis and cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

Induction of IκBα Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor-α Activators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

Expression and Localization of Peroxisome Proliferator-Activated Receptors and Nuclear Factor κB in Normal and Lesional Psoriatic Skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

Nuclear factor-kappaB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2006.03.422

10.1016/J.YJMCC.2006.03.422

7 January 2021

Identifiers

DOI

1 reference

1 April 2018

PubMed ID

16698033

1 reference

1 April 2018